Similar articles for PMID: 16181004

Year	Number of Results
1983	1
1997	1
2000	1
2001	1
2002	2
2003	1
2004	2
2005	4
2006	3
2007	3
2008	2
2009	2
2010	5
2011	7
2012	8
2013	7
2014	6
2015	8
2016	4
2017	4
2018	1
2019	3
2020	4
2021	3
2023	1

1

Delivery of an erythropoietin-Fc fusion protein by inhalation in humans through an immunoglobulin transport pathway.

Dumont JA, Bitonti AJ, Clark D, Evans S, Pickford M, Newman SP. Dumont JA, et al. J Aerosol Med. 2005 Fall;18(3):294-303. doi: 10.1089/jam.2005.18.294. J Aerosol Med. 2005. PMID: 16181004 Clinical Trial.

2

Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway.

Bitonti AJ, Dumont JA, Low SC, Peters RT, Kropp KE, Palombella VJ, Stattel JM, Lu Y, Tan CA, Song JJ, Garcia AM, Simister NE, Spiekermann GM, Lencer WI, Blumberg RS. Bitonti AJ, et al. Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9763-8. doi: 10.1073/pnas.0403235101. Epub 2004 Jun 21. Proc Natl Acad Sci U S A. 2004. PMID: 15210944 Free PMC article.

3

Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics.

Dumont JA, Low SC, Peters RT, Bitonti AJ. Dumont JA, et al. BioDrugs. 2006;20(3):151-60. doi: 10.2165/00063030-200620030-00002. BioDrugs. 2006. PMID: 16724863 Review.

4

Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.

Suzuki T, Ishii-Watabe A, Tada M, Kobayashi T, Kanayasu-Toyoda T, Kawanishi T, Yamaguchi T. Suzuki T, et al. J Immunol. 2010 Feb 15;184(4):1968-76. doi: 10.4049/jimmunol.0903296. Epub 2010 Jan 18. J Immunol. 2010. PMID: 20083659

5

Pulmonary administration of therapeutic proteins using an immunoglobulin transport pathway.

Bitonti AJ, Dumont JA. Bitonti AJ, et al. Adv Drug Deliv Rev. 2006 Oct 31;58(9-10):1106-18. doi: 10.1016/j.addr.2006.07.015. Epub 2006 Aug 12. Adv Drug Deliv Rev. 2006. PMID: 16997417 Review.

6

An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein.

Seijsing J, Lindborg M, Höidén-Guthenberg I, Bönisch H, Guneriusson E, Frejd FY, Abrahmsén L, Ekblad C, Löfblom J, Uhlén M, Gräslund T. Seijsing J, et al. Proc Natl Acad Sci U S A. 2014 Dec 2;111(48):17110-5. doi: 10.1073/pnas.1417717111. Epub 2014 Nov 18. Proc Natl Acad Sci U S A. 2014. PMID: 25406323 Free PMC article.

7

Effect of protein aggregates on characterization of FcRn binding of Fc-fusion therapeutics.

Bajardi-Taccioli A, Blum A, Xu C, Sosic Z, Bergelson S, Feschenko M. Bajardi-Taccioli A, et al. Mol Immunol. 2015 Oct;67(2 Pt B):616-24. doi: 10.1016/j.molimm.2015.06.031. Epub 2015 Aug 5. Mol Immunol. 2015. PMID: 26254986

8

The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy.

Sockolosky JT, Szoka FC. Sockolosky JT, et al. Adv Drug Deliv Rev. 2015 Aug 30;91:109-24. doi: 10.1016/j.addr.2015.02.005. Epub 2015 Feb 19. Adv Drug Deliv Rev. 2015. PMID: 25703189 Free PMC article. Review.

9

Fc-mediated transport of nanoparticles across airway epithelial cell layers.

Vllasaliu D, Alexander C, Garnett M, Eaton M, Stolnik S. Vllasaliu D, et al. J Control Release. 2012 Mar 28;158(3):479-86. doi: 10.1016/j.jconrel.2011.12.009. Epub 2011 Dec 20. J Control Release. 2012. PMID: 22200577

10

Aerosolized protein delivery in asthma: gamma camera analysis of regional deposition and perfusion.

Sangwan S, Agosti JM, Bauer LA, Otulana BA, Morishige RJ, Cipolla DC, Blanchard JD, Smaldone GC. Sangwan S, et al. J Aerosol Med. 2001 Summer;14(2):185-95. doi: 10.1089/08942680152484117. J Aerosol Med. 2001. PMID: 11681650 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed